Obesity And its Effects

 OBESITY AND ITS EFFECTS

Generally, obesity is categorized as generalized obesity (GO) and abdominal obesity (AO). Individuals suffering from obesity have increased mortality and morbidity rates compared to non-obese individuals. With 1.2 billion people, India is the second most populous country in the world, and it is currently experiencing rapid epidemiological transition. Under nutrition due to poverty dominated in the past is being rapidly replaced by obesity associated with affluence. Industrialization and urbanization also contribute to an increased prevalence of obesity.

Generalized obesity refers to fat located throughout the body: in the arms, legs, hips, face, and abdomen. Abdominal obesity, however, is rather localized and refers to fat usually concentrated around one's waist, particularly visceral fat deep inside the abdominal cavity, enveloping internal organs. While both types are long-term risks, abdominal obesity poses a greater risk because visceral fat results in metabolic disruption and inflammation.

Pathophysiology

Obesity is not just a matter of "eating too much and moving too little"; it is a serious chronic disease with excessive adiposity that markedly affects health. The root cause is the disruption of the energy homeostasis system, which refers to the biological process by which energy intake is matched with energy expenditure.

Hormonal Imbalance:

Leptin Resistance: Leptin is a hormone secreted by fat cells, or adipocytes, which notifies the hypothalamus in the brain when an individual is full. However, obese individuals have high levels of leptin resulting from excess fat; their brain will become "resistant" to its signal, causing it to perceive a state of starvation and initiating continued food intake.

Insulin Resistance: Excess free fatty acids and inflammation disrupt insulin signaling. The pancreas then overproduces insulin, called hyperinsulinemia, promoting fat storage, or lipogenesis, inhibiting fat breakdown, or lipolysis.

Gut Hormones: Hormones such as Ghrelin (the "hunger hormone") and GLP-1 (Glucagon-like peptide-1, a satiety hormone) are often dysregulated. In obesity, the post-meal suppression of ghrelin may be blunted, leading to persistent hunger.

 Adipose Tissue Dysfunction:

 Fat tissue is an active endocrine organ. As it expands, it can become hypoxic and infiltrated by immune cells (macrophages), shifting from an anti-inflammatory state to a pro-inflammatory state. This contributes to systemic metabolic damage through chronic low-grade inflammation.

Genetics:

 While single-gene (monogenic) mutations like MC4R deficiency are rare, polygenic obesity is common. This includes hundreds of genetic variants that cumulatively affect appetite regulation, metabolic rate, and the tendency to seek calorie-dense foods.

 Causes

The etiology of obesity is multifactorial, involving a complex interaction between the biology of a person and his environment.

Lifestyle Factors:

 Dietary Quality: The consumption of ultra-processed foods (which contain high sugar, fat, and salt) bypasses natural satiety signals.

Physical Inactivity: Urbanization and technological changes have resulted in increased sedentary behavior globally, reducing Total Daily Energy Expenditure.

Sleep Deprivation: Lack of sleep disrupts the rhythm of the body, raising levels of ghrelin while decreasing leptin, hence increasing carbohydrate cravings.

 Environmental Influences (The "Obesogenic" Environment):

Food Deserts/Swamps: Limited access to affordable fresh produce and an overabundance of fast-food outlets, particularly in lower socioeconomic communities.

 Social Factors: Chronic stress and long working hours often lead to reliance on convenience foods.

Psychological Aspects:

Emotional Eating: Food is often utilized as a coping mechanism during times of stress, anxiety, or trauma.

BED: a distinct psychiatric condition consisting of recurrent episodes of eating large quantities of food; this is often associated with obesity.

 Medications and Medical Conditions:

Some medications, such as antipsychotics, antidepressants, and corticosteroids, have a side effect of weight gain.

 Conditions such as Hypothyroidism and Cushing's syndrome reduce metabolic rate or cause abnormal distribution of fat.

 Side Effects on the Body

It almost affects all organ systems and increases the risk of morbidity and mortality.

Physical Consequences

 Cardiovascular Disease: Obesity acts as a leading driver of hypertension, dyslipidemia, and coronary artery disease and greatly raises the chances of stroke.

Metabolic Disorders:

 Type 2 Diabetes (T2D): About 80-90 % of individuals with T2D are overweight or obese.

 NAFLD/MASLD: Non-Alcoholic Fatty Liver Disease, now increasingly referred to as Metabolic Dysfunction-Associated Steatotic Liver Disease, is increasing rapidly; it may result in cirrhosis.

 Musculoskeletal: The increased mechanical load on joints may accelerate wear and tear, leading to osteoarthritis, more frequently in the knees and hips.

 Cancer: Both the CDC and WHO link obesity to an increased risk of at least 13 types of cancer, including endometrial, breast (post-menopausal), and colorectal cancer.

Psychological Consequences

 Mental Health: Obesity and mental health problems share a bidirectional relationship; obesity increases the chance of depression and anxiety by about 55%.

 Stigma and Discrimination: People frequently experience discrimination against their condition in healthcare, employment, and social settings, further elevating levels of stress and promoting continued maladaptive eating behaviors.

Current Statistics: 2023-2025 Data

 Global Prevalence: More than 1 billion people in the world are living with obesity, according to the World Obesity Atlas 2024.

US Prevalence: CDC data from August 2021 through August 2023 indicates that 40.3% of US adults have obesity, with severe obesity affecting almost 10% of the population.

 Management Strategies

Management for obesity should be regarded as a long-term, multi-tiered process; obesity is a chronic biological disease, rather than a willpower failure.

 Lifestyle Modifications (First-Line)

 Medical Nutrition Therapy: Relies on caloric deficit-restricted diets (500-750 kcal/day) with an improved quality, for instance, the Mediterranean diet.

 Physical Activity: Guidelines recommend 150+ minutes of moderate-intensity aerobic activity per week, plus resistance training to preserve muscle mass during weight loss.

 Behavioral Therapy: Cognitive Behavioral Therapy helps identify and deal with triggers, stress eating, and distorted body images.

 Pharmacotherapy (Medical Intervention)

Recent guidelines, such as the 2024/2025 update, have broadened the indications for AOMs to include all those with a BMI ≥ 30 or ≥ 27 with comorbidities.

 GLP-1 Receptor Agonists: Medications such as semaglutide (Wegovy, Ozempic) mimic the satiety hormone GLP-1, delay gastric emptying, and further suppress appetite. Clinical weight loss in trials has been approximately ~15%.

Dual Agonists: GLP-1/GIP- Tirzepatide, brand name Zepbound, acts on two hormone receptors, exhibiting even greater efficacy: up to 20-25% in trials.

 Older Agents: Options such as Phentermine/Topiramate and Orlistat remain valid for specific patient profiles.

 Bariatric Surgery

It is reserved for patients with severe obesity, BMI 40, or 35 with complications, and is the most effective long-term treatment for metabolic surgery.

 Procedures: includes sleeve gastrectomy, which is a partial removal of the stomach, removing about 80%, and Roux-en-Y gastric bypass, in which changes to the route of food through the intestines are made.

Outcomes: Typically results in the loss of 25-30% total body weight and often places Type 2 Diabetes into remission.

 Multidisciplinary Approach

Success rates are highest when care is delivered by a team including:

Physicians: for medical management.

Registered Dietitians-For nutritional education

 Psychologists-for behavioral support.

 Exercise Physiologists (for planning activities safely)